| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| Carolyn F. Deacon | Q55446060 | ||
| P2093 | author name string | I Vardarli | |
| M A Nauck | |||
| J J Meier | |||
| P2860 | cites work | Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 | Q24682766 |
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 | ||
| Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes | Q28212600 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 | Q28507400 | ||
| Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man | Q28609252 | ||
| Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. | Q33225025 | ||
| DPP-4 inhibitors | Q33308406 | ||
| Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine | Q34180164 | ||
| Attenuated GLP-1 secretion in obesity: cause or consequence? | Q34409856 | ||
| Incretin hormones--an update. | Q34443081 | ||
| Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects | Q35121793 | ||
| Gut hormones and diabetes mellitus | Q35485201 | ||
| Incretins and their analogues as new antidiabetic drugs. | Q35605503 | ||
| The potential role of glucagon-like peptide 1 in diabetes. | Q35768007 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. | Q36075988 | ||
| Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes | Q36293659 | ||
| First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. | Q37105136 | ||
| Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides | Q71566137 | ||
| Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop | Q72801428 | ||
| Colocalization of GLP-1 and GIP in human and porcine intestine | Q73476547 | ||
| Exenatide pharmacokinetics in healthy Chinese subjects | Q81968924 | ||
| Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. | Q37319199 | ||
| Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences | Q37562725 | ||
| Gastric emptying and release of incretin hormones after glucose ingestion in humans | Q39759027 | ||
| Carbohydrate Digestion and Absorption | Q39986385 | ||
| Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes | Q41585674 | ||
| GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell | Q42146257 | ||
| Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors | Q42435619 | ||
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
| Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion | Q42469854 | ||
| Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. | Q42520533 | ||
| Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans | Q43054594 | ||
| Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion | Q43259523 | ||
| The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia | Q43596007 | ||
| Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
| Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor | Q43687822 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. | Q43720039 | ||
| Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion | Q43874494 | ||
| Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides* | Q44049052 | ||
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects | Q44081118 | ||
| The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics | Q44111090 | ||
| Enhanced secretion of glucagon-like peptide 1 by biguanide compounds | Q44207056 | ||
| Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus | Q44467072 | ||
| Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells | Q44480669 | ||
| Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum | Q44753726 | ||
| Neural regulation of glucagon-like peptide-1 secretion in pigs | Q45099394 | ||
| Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes | Q45112803 | ||
| Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. | Q45257473 | ||
| Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors | Q46368613 | ||
| Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus | Q46653146 | ||
| Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients | Q46830628 | ||
| Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance | Q46868130 | ||
| Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients | Q47956988 | ||
| Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. | Q51492143 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. | Q51582586 | ||
| Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. | Q51588717 | ||
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
| Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. | Q51602521 | ||
| Reduced Incretin Effect in Type 2 Diabetes | Q58168459 | ||
| Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy | Q58449247 | ||
| Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas* | Q58449399 | ||
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
| Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve | Q70824569 | ||
| Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut | Q71103325 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 10-18 | |
| P577 | publication date | 2010-09-25 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? | |
| P478 | volume | 54 |
| Q47998883 | A GC-MS untargeted metabolomics analysis in the plasma and liver of rats lacking dipeptidyl-peptidase type IV enzyme activity |
| Q52656812 | A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. |
| Q38020941 | A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes |
| Q42707414 | A computer model simulating human glucose absorption and metabolism in health and metabolic disease states. |
| Q34410733 | A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. |
| Q36428082 | A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes |
| Q34746178 | AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration |
| Q51364117 | Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. |
| Q35769553 | Adaptation of β-Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance |
| Q60462118 | Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic |
| Q26749089 | An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass |
| Q92785535 | An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity |
| Q38639922 | An overview of new GLP-1 receptor agonists for type 2 diabetes |
| Q33607642 | Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes |
| Q35797043 | Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function |
| Q99547668 | Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling |
| Q38200704 | At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose |
| Q33838154 | Bariatric surgery and obesity: influence on the incretins |
| Q48258498 | Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes. |
| Q38267138 | Clinical pharmacology of albiglutide, a GLP-1 receptor agonist |
| Q39255963 | Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor |
| Q92383250 | Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series |
| Q55451044 | Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults. |
| Q36073461 | Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists |
| Q34496741 | Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus |
| Q33585686 | Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes |
| Q45275316 | Current challenges in type 2 diabetes |
| Q38005223 | Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? |
| Q38285608 | DPP-4 inhibitors: focus on safety |
| Q36926350 | Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above? |
| Q35744498 | Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes |
| Q47562217 | Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine |
| Q38165184 | Diabetes and beta cell function: from mechanisms to evaluation and clinical implications |
| Q51332933 | Diabetes mellitus in patients with thalassemia major. |
| Q42536312 | Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. |
| Q37983846 | Diet: friend or foe of enteroendocrine cells--how it interacts with enteroendocrine cells |
| Q51319337 | Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls. |
| Q37995760 | Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes |
| Q27027642 | Digestive physiology of the pig symposium: gut chemosensing and the regulation of nutrient absorption and energy supply |
| Q37130392 | Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent |
| Q64276203 | Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review |
| Q47385874 | Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide. |
| Q44388926 | Early growth and postprandial appetite regulatory hormone responses |
| Q61443707 | Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes |
| Q36460366 | Effect of low- and high-glycemic load on circulating incretins in a randomized clinical trial |
| Q39599827 | Effect of nitrate supplementation on hepatic blood flow and glucose homeostasis: a double-blind, placebo-controlled, randomized control trial |
| Q36550768 | Effect of the ingestion of the palm oil and glutamine in serum levels of GLP-1, PYY and glycemia in diabetes mellitus type 2 patients submitted to metabolic surgery |
| Q88585228 | Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes |
| Q36983097 | Effects of late gestational high-fat diet on body weight, metabolic regulation and adipokine expression in offspring |
| Q53553149 | Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects. |
| Q51371877 | Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. |
| Q35087917 | Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes |
| Q33587806 | Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients |
| Q92228681 | Enhanced postprandial glucagon-like peptide-1 secretion during obesity development has a protective role against glucose intolerance induction in rats |
| Q49691841 | Enteroendocrine K and L cells in healthy and type 2 diabetic individuals |
| Q30420533 | Estimating insulin sensitivity and beta cell function: perspectives from the modern pandemics of obesity and type 2 diabetes |
| Q48106516 | Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. |
| Q51070875 | Exocrine and Endocrine Interactions in Cystic Fibrosis: A Potential Key to Understanding Insulin Secretion in Health and Disease? |
| Q51324113 | Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. |
| Q37900151 | From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy |
| Q30396851 | Functional similarities between the dictyostelium protein AprA and the human protein dipeptidyl-peptidase IV. |
| Q92062268 | GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials |
| Q64888050 | GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients. |
| Q58568275 | GLP-1 Localisation and Proglucagon Gene Expression in Healthy and Diabetic Mouse Ileum |
| Q38055195 | GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. |
| Q45066824 | GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. |
| Q47621594 | GLP-1 response to sequential mixed meals: influence of insulin resistance. |
| Q27000749 | GLP-1, the gut-brain, and brain-periphery axes |
| Q26997149 | GLP-1-based strategies: a physiological analysis of differential mode of action |
| Q51297056 | Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. |
| Q39047697 | Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. |
| Q42730475 | Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes? |
| Q90260620 | Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function |
| Q38320418 | Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science. |
| Q37598515 | Glucagon-like peptide-1 secreting cell function as well as production of inflammatory reactive oxygen species is differently regulated by glycated serum and high levels of glucose |
| Q28660291 | Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener |
| Q38542098 | Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance |
| Q35212540 | Gluco-incretins regulate beta-cell glucose competence by epigenetic silencing of Fxyd3 expression |
| Q64078235 | Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q38218639 | Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q46660587 | Impact of incretin on early-phase insulin secretion and glucose excursion |
| Q48308334 | Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: A novel lipotoxicity paradigm? |
| Q36495535 | Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus |
| Q36241758 | Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance |
| Q38038655 | Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia |
| Q33775600 | Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus |
| Q41882168 | Incretin hormones as immunomodulators of atherosclerosis. |
| Q34878323 | Incretin response in Asian type 2 diabetes: Are Indians different? |
| Q48259139 | Incretin responses to oral glucose and mixed meal tests and changes in fasting glucose levels during 7 years of follow-up: The Hoorn Meal Study |
| Q48215464 | Incretin secretion in humans is under the influence of cannabinoid receptors |
| Q26749165 | Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives |
| Q37837059 | Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. |
| Q44816235 | Incretins, amylin and other gut-brain axis hormones in children with coeliac disease |
| Q41853657 | Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia |
| Q41886708 | Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists! |
| Q38409880 | Islet α cells and glucagon--critical regulators of energy homeostasis |
| Q38838276 | Isolation of Positive Modulator of Glucagon-like Peptide-1 Signaling from Trigonella foenum-graecum (Fenugreek) Seed |
| Q35693608 | Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation |
| Q92353968 | Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes |
| Q51345124 | Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. |
| Q37894446 | Management of type 2 diabetes: new and future developments in treatment |
| Q43235398 | Mechanism of action of DPP-4 inhibitors--new insights |
| Q26781127 | Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1 |
| Q35910421 | Novel Agents for the Treatment of Type 2 Diabetes |
| Q64120628 | Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects |
| Q40029149 | Novel insight into the distribution of L-cells in the rat intestinal tract |
| Q38662831 | Novel insights into the effects of diabetes on gastric motility |
| Q37717838 | On the potential of acarbose to reduce cardiovascular disease |
| Q34893192 | One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr |
| Q27023585 | Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? |
| Q35765440 | Osteocalcin and the Regulation of Glucose Metabolism |
| Q37009157 | Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma |
| Q36006492 | Pancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational Analysis |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q30597265 | Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future |
| Q38061797 | Peripheral signalling involved in energy homeostasis control |
| Q39413300 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum |
| Q36508312 | Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q36637984 | Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis |
| Q35760279 | Physiology of incretins in health and disease |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q47864434 | Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea |
| Q51304866 | Plasma levels of glucagon-like peptide 1 and markers of obesity among young and healthy adults. |
| Q52954771 | Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. |
| Q87951740 | Postprandial glucose-lowering effect of premeal consumption of protein-enriched, dietary fiber-fortified bar in individuals with type 2 diabetes mellitus or normal glucose tolerance |
| Q38797643 | Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes |
| Q38219481 | Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus |
| Q37940632 | Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants |
| Q38195143 | Potential role of skeletal muscle glucose metabolism on the regulation of insulin secretion |
| Q28076530 | Practical combination therapy based on pathophysiology of type 2 diabetes |
| Q38303079 | Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes |
| Q37106937 | Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications |
| Q35766976 | Predicting diabetes using measures of β-cell function |
| Q37704170 | Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus |
| Q38026956 | Recent advances in incretin-based therapies |
| Q58062000 | Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus |
| Q27027877 | Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus |
| Q38078816 | Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. |
| Q48242600 | Sepsis-Induced Activation of Endogenous GLP-1 System is Enhanced in Type 2 Diabetes. |
| Q28397980 | Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy |
| Q36523423 | Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus |
| Q28069065 | Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease |
| Q51339387 | Swim training restores glucagon-like peptide-1 insulinotropic action in pancreatic islets from monosodium glutamate-obese rats. |
| Q37575890 | Testosterone supplementation improves glucose homeostasis despite increasing hepatic insulin resistance in male mouse model of type 2 diabetes mellitus |
| Q92825152 | The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review |
| Q46250756 | The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism |
| Q99412600 | The Mediterranean Diet increases GLP-1 and Oxyntomodulin compared with a Vegetarian Dietary Pattern in Patients with Type 2 Diabetes: a Randomized Controlled Cross-Over Trial |
| Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
| Q51318741 | The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment. |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q51359833 | The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass. |
| Q33849176 | The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo |
| Q37685962 | The effect of diurnal distribution of carbohydrates and fat on glycaemic control in humans: a randomized controlled trial. |
| Q38733474 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions |
| Q51357360 | The incretin hormones: from scientific discovery to practical therapeutics. |
| Q35452743 | The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus |
| Q51373270 | The metabolic syndrome influences the response to incretin-based therapies. |
| Q38826073 | The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. |
| Q26770807 | The role of bile acids in metabolic regulation |
| Q38101677 | The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications |
| Q53262617 | The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. |
| Q38187004 | The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins |
| Q38563239 | Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review |
| Q60921756 | Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss |
| Q26783350 | Treatment of prediabetes |
| Q30404232 | Type 2 diabetes across generations: from pathophysiology to prevention and management |
| Q58447602 | Type 2 diabetes mellitus |
| Q54948267 | Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards. |
| Q38006504 | Update on incretin hormones |
| Q36924521 | Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
| Q35572729 | β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians |
| Q34393402 | β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. |
Search more.